Table 2.
Vaccine Response Rates at Days 30 to 360
| Vaccine Formulation, Day | Subjects With Response, Proportion (%) | Subjects With Titer >1:1024, No. (%) |
|---|---|---|
| 10 µg RSV-PreF | ||
| 30 | 9/14 (64.3) | 6 (42.9) |
| 60 | 5/14 (35.7) | 6 (42.9) |
| 180 | 3/14 (21.4) | 2 (21.4) |
| 360 | 1/14 (7.1) | 2 (14.3) |
| 10 µg RSV-PreF/alum | ||
| 30 | 3/15 (20.0) | 8 (53.3) |
| 60 | 5/15 (33.3) | 8 (53.3) |
| 180 | 3/15 (20.0) | 6 (40.0) |
| 360 | 0/14 (0.0) | 2 (14.3) |
| 30 µg RSV-PreF | ||
| 30 | 7/14 (50.0) | 9 (64.3) |
| 60 | 6/14 (42.9) | 8 (57.1) |
| 180 | 5/15 (33.3) | 7 (46.7) |
| 360 | 4/15 (26.7) | 6 (40.0) |
| 30 µg RSV-PreF/alum | ||
| 30 | 12/14 (85.7) | 12 (85.7) |
| 60 | 10/14 (71.4) | 13 (92.9) |
| 180 | 6/13 (46.2) | 7 (53.8) |
| 360 | 2/12 (16.7) | 4 (33.3) |
| 60 µg RSV-PreF | ||
| 30 | 10/15 (66.7) | 11 (73.3) |
| 60 | 7/15 (46.7) | 9 (60.0) |
| 180 | 3/14 (21.4) | 3 (21.4) |
| 360 | 2/14 (14.3) | 2 (14.3) |
| 60 µg RSV-PreF/alum | ||
| 30 | 11/13 (84.6) | 10 (76.9) |
| 60 | 10/14 (71.4) | 7 (50.0) |
| 180 | 4/12 (33.3) | 3 (25.0) |
| 360 | 3/11 (27.3) | 2 (18.2) |
Vaccine Response were defined as having increased by at least 4-fold from the prevaccination neutralizing antibody (nAb) titer if the prevaccination titer was <7 log2 (ie, <128), by at least 3-fold if the titer was 7–8 log2 (ie, 128–256), by at least 2.5-fold if the titer was 10 log2 (ie, 1024), and by at least 1-fold if the titer was >10 log2 (ie, >1024).
Abbreviation: RSV-PreF, respiratory syncytial virus engineered to preferentially maintain a prefusion conformation.